Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer

Isabel Tundidor, Marta Seijo-Vila, Sandra Blasco-Benito, María Rubert-Hernández, Sandra Adámez, Clara Andradas, Sara Manzano, Isabel Álvarez-López, Cristina Sarasqueta, María Villa-Morales, Carmen González-Lois, Esther Ramírez-Medina, Belén Almoguera, Antonio J. Sánchez-López, Laura Bindila, Sigrid Hamann, Norbert Arnold, Christoph Röcken, Ignacio Heras-Murillo, David SanchoGema Moreno-Bueno, María M. Caffarel, Manuel Guzmán, Cristina Sánchez, Eduardo Pérez-Gómez

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Clinical management of breast cancer (BC) metastasis remains an unmet need as it accounts for 90% of BC-associated mortality. Although the luminal subtype, which represents >70% of BC cases, is generally associated with a favorable outcome, it is susceptible to metastatic relapse as late as 15 years after treatment discontinuation. Seeking therapeutic approaches as well as screening tools to properly identify those patients with a higher risk of recurrence is therefore essential. Here, we report that the lipid-degrading enzyme fatty acid amide hydrolase (FAAH) is a predictor of long-term survival in patients with luminal BC, and that it blocks tumor progression and lung metastasis in cell and mouse models of BC. Together, our findings highlight the potential of FAAH as a biomarker with prognostic value in luminal BC and as a therapeutic target in metastatic disease.

Original languageEnglish
Article number3130
JournalNature Communications
Issue number1
Publication statusPublished - Dec 2023


Dive into the research topics of 'Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer'. Together they form a unique fingerprint.

Cite this